|
Sep 4
|
Johnson & Johnson Wins Over Longtime Holdout for Talc Settlement
|
|
Sep 4
|
Johnson & Johnson adds $1.1 billion to proposed talc settlement
|
|
Sep 4
|
Top Midday Stories: Nvidia Gets DOJ Subpoena as Antitrust Probe Intensifies; Nippon Steel Deal Failure Puts Thousands of US Jobs at Risk, US Steel Says
|
|
Sep 4
|
Johnson & Johnson Ordered to Pay Over $1 Billion in Surgical Robot Acquisition Case
|
|
Sep 4
|
Judge rules J&J owes Auris investors $1 billion related to 2019 robotics deal
|
|
Sep 4
|
3 Dividend Stocks to Double Up on Right Now
|
|
Sep 4
|
Is Johnson & Johnson (JNJ) the Best Cancer Stock to Buy Now?
|
|
Sep 3
|
Johnson & Johnson (JNJ): Among ChatGPT’s Recent Stock Recommendations
|
|
Sep 2
|
Johnson & Johnson (JNJ): A Good 52-Week High Stock to Buy According to Short Sellers
|
|
Sep 2
|
Johnson & Johnson picks Onco360 as pharmacy partner for LAZCLUZE
|
|
Sep 1
|
These Four Dividend Kings Could Thrive Even If The Consumer Falters
|
|
Aug 31
|
Johnson & Johnson's (NYSE:JNJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
|
|
Aug 30
|
J&J targets generalised myasthenia gravis landscape with nipocalimab
|
|
Aug 30
|
JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
|
|
Aug 30
|
J&J launches MatrixSternum fixation system for cardiac surgery in the US
|
|
Aug 29
|
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
|
|
Aug 29
|
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
|
|
Aug 29
|
J&J submits touted autoimmune disease drug for FDA approval
|
|
Aug 29
|
Biocon Biologics signs agreement with Janssen to market Bmab 1200
|
|
Aug 29
|
The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly
|